Friday 18th August 2023 update: login access to this repository is currently paused pending an upgrade to a new DSpace version in September 2023. If you have a query about submitting to this repository please contact the library repository administrators via the 'Contact Us' link in at the bottom of this page. FAO repository administrators: please do not add new items to the repository in this time and contact Atmire if any query.
Differential expression of glycoprotein IV on monocyte subsets following high-fat diet feeding and the impact of short-term low-dose aspirin treatment
dc.contributor.author | Mokgalaboni, K. | |
dc.contributor.author | Dludla, P.V. | |
dc.contributor.author | Mkandla, Z. | |
dc.contributor.author | Mutize, T. | |
dc.contributor.author | Nyambuya, T.M. | |
dc.contributor.author | Mxinwa, V. | |
dc.contributor.author | Nkambule, B.B. | |
dc.date.accessioned | 2023-04-17T12:59:32Z | |
dc.date.available | 2023-04-17T12:59:32Z | |
dc.date.issued | 2020-08-01 | |
dc.identifier.citation | Mokgalaboni K, Dludla PV, Mkandla Z, Mutize T, et al. Differential expression of glycoprotein IV on monocyte subsets following high-fat diet feeding and the impact of short-term low-dose aspirin treatment. Metabol Open. 2020. | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.metop.2020.100047 | |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/33015602/ | |
dc.identifier.uri | https://infospace.mrc.ac.za/handle/11288/595308 | |
dc.description.abstract | Objective: To assess the levels of glycoprotein GPIV (CD36) expression on peripheral blood monocyte subsets, in a mouse model of glucose intolerance. Moreover, to determine the effect of; low-dose aspirin (LDA) alone, LDA combined with metformin, or clopidogrel alone, on the expression of CD36 on subsets of circulating monocytes. Method: The study consisted of two experimental phases. In experiment one, the mice (n = 14) were randomised to receive a low-fat diet (LFD) or a high-fat diet (HFD) for eight weeks. Whereas the secondary phase of the experiment, comprised of twenty-four HFD-fed mice treated with LDA alone (3 mg/kg), or in combination with metformin (150 mg/kg), or clopidogrel alone (10 mg/kg) for six weeks. The surface expression of CD36 on monocytes was measured using flow cytometry. Result: The levels of CD36 expression on monocytes were upregulated in the HFD-fed compared to LFD-fed group (p < 0.05). In addition, HFD group showed; no significant changes in body weight (p = 0.3848), however, blood glucose (p = 0.0002) and insulin (p = 0.0360) levels were markedly increased following HFD-feeding. Interestingly, all treatments reduced the expression of CD36 on monocytes, decreased fasting blood glucose levels (p = 0.0024) and increased circulating monocyte levels (p = 0.0217) when compared to the untreated HFD group. Moreover, treatment with LDA alone increased basophils levels (p = 0.0272), while when combined with metformin showed an improved effect in enhancing eosinophil levels (p = 0.0302). Conclusion: HFD-feeding increased the expression of CD36 on monocyte subsets. LDA as a monotherapy or combined with metformin was as effective as clopidogrel monotherapy, in downregulating the expression of CD36 on monocyte subsets. These treatments may be of relevance in preventing cardiovascular complications associated with impaired glucose tolerance. | en_US |
dc.description.sponsorship | Funding statement BBN is partially funded by the National Research Foundation of South Africa (Grant Number: 107519) and research reported in this publication was supported by the South African Medical Research Council (SAMRC) under a Self-Initiated Research (Grant Number: 9894). BBN is also a University of KwaZulu-Natal (UKZN) Developing Research Innovation, Localisation and Leadership in South Africa (DRILL) fellow. DRILL is an NIH D43 grant (D43TW010131) awarded to UKZN in 2015 to support a research training and induction programme for early-career academics. PV Dludla was partially supported as a Post-Doctoral Fellow by funding from the SAMRC through its division of Research Capacity Development under the Intra-Mural Postdoctoral Fellowship Programme from funding received from the South African Treasury. The content hereof is the sole responsibility of the authors and do not necessarily represent the official views of the SAMRC or the funders. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | Antiplatelet drug | en_US |
dc.subject | CD36 | en_US |
dc.subject | Impaired glucose tolerance | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Monocytes | en_US |
dc.subject | Prediabetes | en_US |
dc.subject | T2DM | en_US |
dc.subject | Aspirin treatment | en_US |
dc.title | Differential expression of glycoprotein IV on monocyte subsets following high-fat diet feeding and the impact of short-term low-dose aspirin treatment | en_US |
dc.type | Article | en_US |
dc.contributor.department | Phiwayinkosi V Dludla: Biomedical Research and Innovation Platform (BRIP), South African Medical Research Council. | en_US |
dc.identifier.journal | Metabolism Open | en_US |
dc.research.unit | Biomedical Research and Innovation Platform | en_US |
dc.date.epub | 2020 |